What is in tirzepatide?

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [1]. It is a novel class of injectable medication designed for the treatment of type 2 diabetes [1]. Tirzepatide works by mimicking the actions of natural hormones that regulate blood sugar and appetite [2].

How does tirzepatide help manage blood sugar?

Tirzepatide enhances insulin secretion from the pancreas in a glucose-dependent manner, meaning it releases more insulin when blood sugar levels are high [1]. It also reduces the amount of glucose released by the liver and slows down the emptying of the stomach, which helps to prevent rapid spikes in blood sugar after meals [1].

What are the potential benefits of tirzepatide beyond blood sugar control?

In clinical trials, tirzepatide has demonstrated significant reductions in body weight in addition to its glucose-lowering effects [3]. This dual action makes it a potentially valuable treatment option for individuals with type 2 diabetes who also struggle with obesity [3].

When did tirzepatide become available and who developed it?

Tirzepatide was developed by Eli Lilly and Company. It received FDA approval for the treatment of type 2 diabetes in May 2022 [4].

What is the current patent status of tirzepatide?

Information on the patent exclusivity for tirzepatide can be found on DrugPatentWatch.com [5]. Patent expirations and challenges can impact the availability of generic versions of the drug in the future [5].